Figure 3.

The short-term (3 months) efficacy comparison of antivascular endothelial growth factor (anti-VEGF) therapy for three subtypes of neovascular age-related macular degeneration (nAMD). (a) Vision improvement of the three types of nAMD, measured by logarithm of the minimum angle of resolution (logMAR), were −0.09 (95% confidence interval (CI): −0.12, −0.06), −0.18 (95% CI: −0.46, 0.10), and −0.23 (95% CI: −0.30, −0.16). (b) Macular thickness decreases were −104.83 (95% CI: −156.93, −52.72), −130.76 (95% CI: −181.07, −80.45), and −196.29 (95% CI: −285.05, −107.53) μm, respectively.